IL135905A0 - Vaccines with an ltb adjuvant - Google Patents

Vaccines with an ltb adjuvant

Info

Publication number
IL135905A0
IL135905A0 IL13590598A IL13590598A IL135905A0 IL 135905 A0 IL135905 A0 IL 135905A0 IL 13590598 A IL13590598 A IL 13590598A IL 13590598 A IL13590598 A IL 13590598A IL 135905 A0 IL135905 A0 IL 135905A0
Authority
IL
Israel
Prior art keywords
vaccines
immunogen
vaccine
ltb
adjuvant
Prior art date
Application number
IL13590598A
Other languages
English (en)
Original Assignee
Duphar Int Res
Universiteit Van Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duphar Int Res, Universiteit Van Groningen filed Critical Duphar Int Res
Publication of IL135905A0 publication Critical patent/IL135905A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL13590598A 1997-11-25 1998-11-24 Vaccines with an ltb adjuvant IL135905A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203671A EP0919243A1 (en) 1997-11-25 1997-11-25 Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
PCT/EP1998/007553 WO1999026654A1 (en) 1997-11-25 1998-11-24 Vaccines with an ltb adjuvant

Publications (1)

Publication Number Publication Date
IL135905A0 true IL135905A0 (en) 2001-05-20

Family

ID=8228966

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13590598A IL135905A0 (en) 1997-11-25 1998-11-24 Vaccines with an ltb adjuvant
IL135905A IL135905A (en) 1997-11-25 2000-05-01 Vaccines that contain LTB helps

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL135905A IL135905A (en) 1997-11-25 2000-05-01 Vaccines that contain LTB helps

Country Status (25)

Country Link
US (1) US6793928B1 (xx)
EP (2) EP0919243A1 (xx)
JP (1) JP4235359B2 (xx)
KR (1) KR100575019B1 (xx)
CN (1) CN1227032C (xx)
AT (1) ATE238809T1 (xx)
AU (1) AU747061C (xx)
BR (1) BR9815413A (xx)
CA (1) CA2311492C (xx)
CZ (1) CZ299770B6 (xx)
DE (1) DE69814177T2 (xx)
DK (1) DK1071456T3 (xx)
ES (1) ES2198089T3 (xx)
HK (1) HK1031102A1 (xx)
HU (1) HU226214B1 (xx)
IL (2) IL135905A0 (xx)
NO (1) NO324690B1 (xx)
NZ (1) NZ504396A (xx)
PL (1) PL190925B1 (xx)
PT (1) PT1071456E (xx)
RU (1) RU2211050C2 (xx)
SK (1) SK284572B6 (xx)
TR (1) TR200001485T2 (xx)
UA (1) UA72199C2 (xx)
WO (1) WO1999026654A1 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US7914791B1 (en) 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine
CA2331832A1 (en) * 1998-05-08 1999-11-18 University Of Bristol E.coli heat-labile enterotoxin subunit b (etxb) as an immunomodulator
AU2003261492B2 (en) * 1998-05-08 2006-09-07 Trident Pharmaceuticals, Inc. Vaccine
WO2001035993A2 (en) * 1999-10-18 2001-05-25 Chiron Corporation Compositions and methods for stimulating an immune response against infectious agents
IL158140A0 (en) * 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
WO2005079841A2 (en) * 2003-12-09 2005-09-01 Iomai Corporation Gm1 binding deficient exotoxins for use as immunoadjuvants
US8211442B2 (en) 2005-08-05 2012-07-03 The University Of Tokushima Mucosal vaccine enabling switching from production of IgA antibody to production of both of IgA and IgG antibodies
TWI397419B (zh) * 2006-03-22 2013-06-01 Abbott Biologicals Bv 病毒顆粒的鼻內或吸入給藥
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
KR20090079938A (ko) * 2006-10-12 2009-07-22 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. 텔로머라제 역전사효소 융합 단백질, 이를 암호화하는 뉴클레오타이드, 및 이들의 용도
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
AU2008343745B2 (en) 2007-10-01 2012-05-10 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
EP2806890A4 (en) 2012-01-26 2015-09-02 Longhorn Vaccines & Diagnostics Llc COMPOSITE ANTIGENIC SEQUENCES AND VACCINES
KR101887040B1 (ko) * 2012-06-20 2018-08-09 고쿠리츠다이가쿠호징 도쿄다이가쿠 점막 면역 부활화제 및 hpv 감염증 치료용 경구 의약 조성물
CN106170551B (zh) 2013-12-16 2020-01-07 财团法人农业科技研究院 生产不耐热肠毒素b亚单位的质粒、方法及其套组
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
KR20200083540A (ko) * 2017-11-01 2020-07-08 머크 샤프 앤드 돔 코포레이션 시토메갈로바이러스의 안정한 제형
WO2019139891A1 (en) 2018-01-09 2019-07-18 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
US11654184B2 (en) 2018-03-20 2023-05-23 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
CA3094173A1 (en) 2018-03-20 2019-09-26 Synthetic Biologics, Inc. Intestinal alkaline phosphatase formulations
TWI811673B (zh) * 2020-05-08 2023-08-11 昱厚生技股份有限公司 使用免疫調節劑及包含其之疫苗組合物預防或治療冠狀病毒感染之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH589453A5 (xx) 1974-01-14 1977-07-15 Sandoz Ag
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
IL92578A0 (en) * 1988-12-07 1990-08-31 Univ Leicester Heat-labile toxin b subunit fusion proteins and their preparation
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB

Also Published As

Publication number Publication date
NO324690B1 (no) 2007-12-03
HU226214B1 (en) 2008-06-30
DE69814177D1 (de) 2003-06-05
PL340635A1 (en) 2001-02-12
HK1031102A1 (en) 2001-06-01
TR200001485T2 (tr) 2001-12-21
EP1071456B1 (en) 2003-05-02
PL190925B1 (pl) 2006-02-28
WO1999026654A1 (en) 1999-06-03
KR100575019B1 (ko) 2006-05-02
UA72199C2 (en) 2005-02-15
CN1227032C (zh) 2005-11-16
AU747061B2 (en) 2002-05-09
CZ20001895A3 (cs) 2000-10-11
IL135905A (en) 2006-08-01
EP1071456A1 (en) 2001-01-31
HUP0100058A1 (hu) 2001-05-28
AU1875099A (en) 1999-06-15
JP2001523729A (ja) 2001-11-27
RU2211050C2 (ru) 2003-08-27
NO20002613D0 (no) 2000-05-22
SK7762000A3 (en) 2000-11-07
HUP0100058A3 (en) 2003-03-28
BR9815413A (pt) 2000-10-17
SK284572B6 (sk) 2005-06-02
NZ504396A (en) 2002-09-27
ES2198089T3 (es) 2004-01-16
NO20002613L (no) 2000-05-22
JP4235359B2 (ja) 2009-03-11
DE69814177T2 (de) 2004-04-08
AU747061C (en) 2005-02-24
EP0919243A1 (en) 1999-06-02
CZ299770B6 (cs) 2008-11-19
PT1071456E (pt) 2003-09-30
CA2311492A1 (en) 1999-06-03
CN1280504A (zh) 2001-01-17
DK1071456T3 (da) 2003-06-02
CA2311492C (en) 2011-10-18
KR20010032425A (ko) 2001-04-16
ATE238809T1 (de) 2003-05-15
US6793928B1 (en) 2004-09-21

Similar Documents

Publication Publication Date Title
PL340635A1 (en) Vaccines with the ltb adjuvant
DE60012711D1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe
HU9502105D0 (en) Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
ZA938203B (en) Urease-based vaccine against helicobacter infection
WO2000047222A3 (de) Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
MX9702336A (es) Composiciones de vacuna.
EP0672116A4 (en) DELETION MUTANTS USED AS CHOLERA VACCINES.
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
DE69327553D1 (de) E.Coli P-Fimbriae als immunogener Träger gegen GnRH
WO1999065518A3 (en) Lt and ct in parenteral immunization methods against helicobacter infection
AU4208497A (en) Helicobacter pylori live vaccine
CY2540B1 (en) Vaccine against mumps containing a jeryl-lynn virus strain
GB9818133D0 (en) Vaccine
WO2000074630A3 (en) Dna vaccine for protecting an avian against infectious bursal disease virus
CA2388054A1 (en) Compositions and methods for stimulating an immune response against infectious agents
DK0721782T3 (da) Influenzavaccine indeholdende pertussistoksin

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed